Small bowel adenocarcinoma.
Small bowel cancers are rare, accounting for only about 6000 cases/year in the United States, approximately 25% of which are small bowel adenocarcinomas. Small bowel adenocarcinomas have traditionally been considered to be highly fatal due to their nonspecific presentation at the time of diagnosis, and to the lack of responsiveness to older chemotherapy regimens. However, that paradigm may be changing. Newer diagnostic techniques such as video capsule and double balloon enteroscopy may facilitate earlier diagnosis. In addition, modern chemotherapy regimens have produced improved response rates and survival rates, when compared to historical controls. Still, there remains great need for multi-institutional, cooperative group studies to define the optimal treatment of small bowel adenocarcinoma, both in the adjuvant and advanced/metastatic setting.
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW, Washington, DC 20007, USA.
Majed El
ME
Zouhairi
Allison
A
Venner
Aline
A
Charabaty
Michael J
MJ
Pishvaian
D000230:Adenocarcinoma / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D017668:Age of Onset; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D007421:Intestine, Small / Q000473:pathology; D008297:Male; D051379:Mice; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil